NK Cells Treatment for COVID-19

Status Completed

Clinical Trial Summary

Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCoV infection. Natural killer (NK) cells are innate lymphocytes that may serve as useful effectors against danger infection. The purpose of this clinical investigation is to evaluate the safety and efficiency of NK Cells in combination with standard therapy for pneumonia patients infected with 2019-nCoV.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04280224
Study type	Interventional
Source	Xinxiang medical university
Contact
Status	Completed
Phase	Phase 1
Start date	February 15, 2020
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04798716` - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19	Phase 1/Phase 2
Completed	`NCT05305456` - Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19	Phase 3
Recruiting	`NCT04314271` - The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia
Recruiting	`NCT04282902` - A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection	Phase 3
Withdrawn	`NCT04285190` - The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19	N/A
Recruiting	`NCT04283396` - Study for Novel Coronavirus Pneumonia (NCP)
Active, not recruiting	`NCT04273763` - Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)	N/A
Completed	`NCT04273321` - Efficacy and Safety of Corticosteroids in COVID-19	N/A
Enrolling by invitation	`NCT04365309` - Protective Effect of Aspirin on COVID-19 Patients	Phase 2/Phase 3
Completed	`NCT04645407` - Effects of Fuzheng Huayu Tablets on COVID-19	Phase 4